SCHEMBL23364293

SCHEMBL23364293

CCOP(=O)(Cc1cc(Br)ccc1OC)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
TDP1 Q9NUW8 3/20 0.44
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
USP2 O75604 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12798326 0.83 EGFR (0.40) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL3042909 0.82 TAAR1 (0.43) MAPTHTTL3MBTL1TSHR
SCHEMBL30791331 0.82 CCNT1 (0.39) MAPTHTTL3MBTL1
SCHEMBL23525666 0.82 CCNT1 (0.39) MAPTHTTL3MBTL1
SCHEMBL5166123 0.80 EGFR (0.39) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL12215858 0.80 TAAR1 (0.39) TDP1MAPTHTTL3MBTL1TSHR
SCHEMBL9167237 0.79 ALDH1A1 (0.50) TDP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12892630 0.79 TAAR1 (0.49) MAPTHTTL3MBTL1TSHR
SCHEMBL30791379 0.78 SMN1; SMN2 (0.49) KDM4EALDH1A1KMT2ASMN1; SMN2MAPT
SCHEMBL12132980 0.78 TSHR (0.55) ALDH1A1MEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4058435-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2022-09-21 EP disclosed
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2022-09-08 US disclosed
CN-114728905-A Therapeutic compounds and methods of use 基因泰克公司 2022-07-08 CN disclosed
WO-2021097110-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2021-05-20 WO disclosed
WO-2021097110-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, NQO1, PCSK9 KDM4E 2745/4885TDP1 1486/4885ALDH1A1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.